| Literature DB >> 22919604 |
François Vandenesch1, G Lina, Thomas Henry.
Abstract
One key aspect of the virulence of Staphylococcus aureus lies in its ability to target the host cell membrane with a large number of membrane-damaging toxins and peptides. In this review, we describe the hemolysins, the bi-component leukocidins (which include the Panton Valentine leukocidin, LukAB/GH, and LukED), and the cytolytic peptides (phenol soluble modulins). While at first glance, all of these factors might appear redundant, it is now clear that some of these factors play specific roles in certain S. aureus life stages and diseases or target specific cell types or species. In this review, we present an update of the literature on toxin receptors and their cell type and species specificities. Furthermore, we review epidemiological studies and animal models illustrating the role of these membrane-damaging factors in various diseases. Finally, we emphasize the interplay of these factors with the host immune system and highlight all their non-lytic functions.Entities:
Keywords: PSM; Panton Valentine leukocidin; Staphylococcus aureus; hemolysin; inflammasome; leukocidin; neutrophil; pore-forming toxin
Mesh:
Substances:
Year: 2012 PMID: 22919604 PMCID: PMC3417661 DOI: 10.3389/fcimb.2012.00012
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Species and cell type specificities of the various hemolysins, bi-component leukocidins, and PSMs.
| Toxin/peptide | Target cell (% lysis) | Dose | Reference |
|---|---|---|---|
| α-Hemolysin | Human lymphocyte (80%) | 100 ng/ml | Valeva et al. ( |
| Jurkat cells and peripheral blood monocytes (0%: resistant) | 100 ng/ml up to 20 μg/ml | Bantel et al. ( | |
| Human granulocytes/neutrophils (0%: resistant) | 10 μg/ml up to 20 μg/ml | Valeva et al. ( | |
| Human monocytes (90%) | 80 ng/ml | Bhakdi et al. ( | |
| A549 (40%) | 375 nM (10 μg/ml) | Wilke and Bubeck Wardenburg ( | |
| PVL | Murine alveolar macrophages | (280 nM) 10 μg/ml | Ziebandt et al. ( |
| Human macrophages (90%) | 100 ng/ml | Perret et al. ( | |
| Human neutrophils (90%) | 80 ng/ml | Loffler et al. ( | |
| Murine neutrophils (20%) | 40 μg/ml | Loffler et al. ( | |
| Rabbit neutrophils (90%) | 60 ng/ml | Loffler et al. ( | |
| LukAB/GH | Human polymorphonuclear cells (60%) | 2.5 μg/ml | Dumont et al. ( |
| LukED | Murine peritoneal exudate cells (60%) | 2.5 μg/ml | Alonzo et al. ( |
| β-Hemolysin | Sheep erythrocyte (50%) | 500 ng/ml | Tajima et al. ( |
| HUVEC (resistant) | 1 μg/ml | Tajima et al. ( | |
| Human fibroblast (resistant) | 1 μg/ml (5 μg/ml) | Walev et al. ( | |
| T lymphocyte (resistant) | 1 μg/ml (5 μg/ml) | Walev et al. ( | |
| Granulocyte (resistant) | 1 μg/ml (5 μg/ml) | Walev et al. ( | |
| Monocyte (50%) | 0.001 μg/ml (5 ng/ml) | Walev et al. ( | |
| Lymphocyte (NA) | 10 μg/ml | Huseby et al. ( | |
| δ-Hemolysin | HeLa | 0.5 Hemolytic units/ml | Thelestam et al. ( |
| Human neutrophils (5%) | 10 μg/ml | Wang et al. ( | |
| PSMα1 | Human neutrophils (7.5%) | 10 μg/ml | Wang et al. ( |
| PSMα2 | Human neutrophils (10%) | 10 μg/ml | Wang et al. ( |
| PSMα3 | Human neutrophils (60%) | 10 μg/ml | Wang et al. ( |
| PSM-mec | Human neutrophils (12%) | 50 μg/ml | Queck et al. ( |
| PSMβ1 | Human blood (weak) | 1 μg/ml | Cheung et al. ( |
.
.
.
.
.
Membrane-damaging factors and their role in various diseases in various animal models.
| Disease | Animal | Inoculum (strain type) | Virulence factor | Phenotype of the animal infected with the mutant strain as compared to the WT strain | Reference |
|---|---|---|---|---|---|
| Skin infection | Rabbit | 5 × 108 MRSA (USA 300 Lac) | hla | Decreased cfu, decreased abscess size | Kobayashi et al. ( |
| PSMα | Decreased cfu, decreased abscess size | ||||
| PVL | Decrease cfu, increased abscess size at resolution stage | ||||
| Skin infection | Rabbit | 108 MRSA (USA 300 Lac) | PVL | Decreased lesion size, decreased necrotic lesion size | Lipinska et al. ( |
| Osteomyelitis | Rabbit | 4 × 108 MRSA (USA 300 Lac) | PVL | No bone deformation at day 7, decreased cfu at day 28 | Cremieux et al. ( |
| Necrotizing soft tissue infection | Mice | 109 cfu | PVL | No difference in cfu, No difference in skin lesion size, decreased muscle lesions in BalB/c mice not in C57BL6J mice | Tseng et al. ( |
| Necrotizing pneumonia | Rabbit | 1010 cfu (USA 300 SF8300) | PVL | Decreased mortality, decreased inflammation | Diep et al. ( |
| Necrotizing pneumonia | Mice | Purified PVL (3 μg LukS + 3 μg LukF) | PVL | Death, neutrophil recruitment | Labandeira-Rey et al. ( |
| Necrotizing pneumonia | Mice | 2.107 cfu (LUG855) | PVL | Decreased mortality, decreased inflammation | |
| Bacteremia | Rabbit | PVL | Decreased cfu in the kidney at 24–48 h PI not at 72 h PI | Diep et al. ( | |
| Bacteremia | Mice | 1.106 cfu (USA 300 Lac) | LukAB/GH | Decreased cfu in the kidney at day 4 PI | Dumont et al. ( |
| Bacteremia | Mice | 108 cfu (Mw2) | PSMα | Decreased mortality, less TNFα | Wang et al. ( |
| PSMβ | No role | ||||
| hld | Decreased mortality, less TNFα | ||||
| Skin infection | Mice | 107 cfu (Mw2) | PSMα | Decreased lesion size | Wang et al. ( |
| PSMβ | Increased lesion size | ||||
| hld | No role | ||||
| Bacteremia | Mice | 108 cfu (MSA890) | PSM-mec | Decreased mortality | Queck et al. ( |
| Skin infection | Mice | 107 cfu (MSA890) | PSM-mec | No dermonecrosis, no weight loss | |
| Pneumonia | Mice | 2–4 × 108 cfu (Lac) | hla | Decreased mortality | Bubeck Wardenburg et al. ( |
| Pneumonia | Mice | 2–4 × 108 cfu (MW2 or Lac) | PVL | No effect | Bubeck Wardenburg et al. ( |
| Pneumonia | Mice | 1.2 × 108 cfu (8325.4) | hlb | Decreased inflammation, decreased lung injury | Hayashida et al. ( |
| Pneumonia | Mice | 15 μg hlb | hlb | Increased inflammation, increased lung injury | Hayashida et al. ( |
| Endophthalmitis | Rabbit | 102 cfu | hlg | Decreased cfu at day 4 PI, decreased inflammation at day 3 PI | Supersac et al. ( |
| Brain abscess | Mice | 105 cfu (RN6390) | hla | Decreased cfu, decreased inflammation | Kielian et al. ( |
Due to controversial results, we present a larger coverage on studies testing the role of PVL. .
Figure 1Interplay between membrane-damaging (poly)peptides and the innate immune system. (1) In physiological conditions, differences in [Ca2+] and [K+] are actively maintained between the extracellular space and the cytosol. (2) Insertion of a PFT or membrane damage leads to a direct or indirect rise in [Ca2+]i. (3) Similarly, engagement of FPR2 by PSMα triggers an increase in [Ca2+]i. (4) [Ca2+]i controls NF-κB and (5) cPLA2 activation. (6) TLR2 and 4 might also trigger NF-κB translocation in the nucleus by sensing LukS-PV and LukF-PV. (7) Insertion of a PFT or membrane damage leads to a rapid fall in [K+]i, leading to (8) MAP kinase and (9) NLRP3 inflammasome activation. (10) Ceramide generated by β-hemolysin might also directly activate the NLRP3 inflammasome. (11) In addition, ceramide has been reported to inhibit IL-8 secretion.
Figure 2Non-lytic functions of hemolysins, bi-component toxins, and PSMs. (1) E-cadherin is important for maintaining tight junctions and epithelial barrier function. α-Hemolysin binds ADAM10 and relocalizes it to E-cadherin-containing microdomains. ADAM10 cleaves E-cadherin, leading to loss in epithelial barrier function. (2) Exposure of the underlying glycosaminoglycans-rich extracellular matrix to LukS-PV signal peptide favors S. aureus adhesion. (3) PSM-mec RNA controls the transcription of virulence factors, including PSMα. (4) β-Hemolysin binds DNA, forming nucleoproteins nucleating S. aureus biofilm. PSMβ acts as surfactant, promoting the formation of intra-biofilm tunnels and bacterial dissemination from biofilms. PSM-mec enhances biofilm formation (5) In addition, PSMs have antibacterial activity, which may be relevant in lysing competing colonizing bacteria. (6) Finally, PSMs in synergy with β-hemolysin participate in phagosome lysis and escape into the host cytosol.